{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:00:22Z","timestamp":1792206022412,"version":"4.4.0"},"reference-count":73,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jtim-2026-0007_s_011\">\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Non-alcoholic fatty liver disease (NAFLD) has become a growing global public health concern. Effective therapeutic strategies for NAFLD remain urgently needed. Liver-on-a-chip (LC) technology offers an innovative platform for NAFLD modeling and drug development. This study aimed to develop a biomimetic liver-chip using co-cultured human hepatocyte (HepaRG) with hepatic stellate and endothelial cells to model NAFLD, and evaluate the therapeutic potential of scalable telomerase reverse transcriptase (hTERT)-immortalized umbilical cord mesenchymal stem cell-derived exosomes (TMSC-Exo).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0007_s_012\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HepaRG cells, hepatic stellate cells, and endothelial cells were used to construct a dual-chamber biocompatible LC. The NAFLD model was induced by free fatty acid (FFA) and applied to evaluate the efficacy of resmetirom and TMSC-Exo for the treatment of NAFLD. Moreover, the high-fat (HF) diet-induced mouse model was analyzed to verify the in vitro results. Proteomic analyses were performed to explore the molecular mechanisms involved in the development of NAFLD and the effect of TMSC-Exo in treating NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0007_s_013\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Cells cultured in LC showed better viability compared to those in the Transwell system. The on-chip NAFLD model mimicked the characteristics of NAFLD\n                      <jats:italic>in vivo<\/jats:italic>\n                      , including intracellular lipid accumulation and impaired hepatocyte functions in albumin synthesis, levels of urea, CYP1A2, and CYP3A4. Both TMSC-Exo and resmetirom displayed a significant effect in reducing the lipid accumulation in the on-chip NAFLD model. The TMSC-Exo showed superior effects in elevating the levels of albumin, urea, CYP1A2, and CYP3A4. The therapeutic effects of TMSC-Exo were also confirmed in the NAFLD mouse models. Proteomic analysis found that the top 15 up- and down-regulated differentially expressed proteins in NAFLD models compared to the control group were mainly associated with lipid metabolism, endoplasmic reticulum stress, and inflammation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jtim-2026-0007_s_014\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our on-chip NAFLD model successfully recapitulated key pathological features of hepatic steatosis and functional impairment. Using this model, we evaluated TMSC-Exo and demonstrated its significant therapeutic efficacy against NAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jtim-2026-0007","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T10:18:39Z","timestamp":1771323519000},"page":"134-149","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model"],"prefix":"10.1515","volume":"14","author":[{"given":"Shujiao","family":"He","sequence":"first","affiliation":[{"name":"General Surgery Centre, Department of Hepatobiliary Surgery II, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University , Guangzhou , Guangdong Province , China"},{"name":"Central Laboratory of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People\u2019s Hospital of Shenzhen , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Wang","sequence":"additional","affiliation":[{"name":"Central Laboratory of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People\u2019s Hospital of Shenzhen , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghui","family":"Li","sequence":"additional","affiliation":[{"name":"General Surgery Centre, Department of Hepatobiliary Surgery II, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University , Guangzhou , Guangdong Province , China"},{"name":"Central Laboratory of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People\u2019s Hospital of Shenzhen , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Fang","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shantou University Medical College , Shantou , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Shantou University Medical College , Shantou , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Food Hygiene, Lanzhou University School of Public Health , Lanzhou , Gansu Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nutrition and Food Hygiene, Lanzhou University School of Public Health , Lanzhou , Gansu Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[{"name":"Central Laboratory of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People\u2019s Hospital of Shenzhen , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Gao","sequence":"additional","affiliation":[{"name":"General Surgery Centre, Department of Hepatobiliary Surgery II, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University , Guangzhou , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[{"name":"General Surgery Centre, Department of Hepatobiliary Surgery II, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University , Guangzhou , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Li","sequence":"additional","affiliation":[{"name":"General Surgery Centre, Department of Hepatobiliary Surgery II, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University , Guangzhou , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People\u2019s Hospital of Shenzhen , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7790-6455","authenticated-orcid":false,"given":"Qing","family":"Peng","sequence":"additional","affiliation":[{"name":"General Surgery Centre, Department of Hepatobiliary Surgery II, Institute of Regenerative Medicine, Zhujiang Hospital, Southern Medical University , Guangzhou , Guangdong Province , China"},{"name":"Central Laboratory of The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen & Longgang District People\u2019s Hospital of Shenzhen , Shenzhen , Guangdong Province , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026021906293001311_j_jtim-2026-0007_ref_001","doi-asserted-by":"crossref","unstructured":"Amini-Salehi E, Letafatkar N, Norouzi N, Joukar F, Habibi A, Javid M, et al. Global Prevalence of Nonalcoholic Fatty Liver Disease: An Updated Review Meta-Analysis comprising a Population of 78 million from 38 Countries. Arch Med Res 2024;55:103043.","DOI":"10.1016\/j.arcmed.2024.103043"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_002","doi-asserted-by":"crossref","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 2024;73:691-702.","DOI":"10.1136\/gutjnl-2023-330595"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_003","doi-asserted-by":"crossref","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-2224.","DOI":"10.1016\/S0140-6736(20)32511-3"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_004","doi-asserted-by":"crossref","unstructured":"Jin M, Yi X, Liao W, Chen Q, Yang W, Li Y, et al. Advancements in stem cell-derived hepatocyte-like cell models for hepatotoxicity testing. Stem Cell Res Ther 2021;12:84.","DOI":"10.1186\/s13287-021-02152-9"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_005","doi-asserted-by":"crossref","unstructured":"Yang S, Ooka M, Margolis RJ, Xia M. Liver three-dimensional cellular models for high-throughput chemical testing. Cell Rep Methods 2023;3:100432.","DOI":"10.1016\/j.crmeth.2023.100432"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_006","doi-asserted-by":"crossref","unstructured":"Hassan S, Sebastian S, Maharjan S, Lesha A, Carpenter AM, Liu X, et al. Liver-on-a-Chip Models of Fatty Liver Disease. Hepatology 2020;71:733-740.","DOI":"10.1002\/hep.31106"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_007","doi-asserted-by":"crossref","unstructured":"Yang J, Hirai Y, Iida K, Ito S, Trumm M, Terada S, et al. Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease. Commun Biol 2023;6:310.","DOI":"10.1038\/s42003-023-04710-8"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_008","doi-asserted-by":"crossref","unstructured":"Du K, Li S, Li C, Li P, Miao C, Luo T, et al. Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply. Acta Biomater 2021;134:228-239.","DOI":"10.1016\/j.actbio.2021.07.013"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_009","doi-asserted-by":"crossref","unstructured":"Wiriyakulsit N, Keawsomnuk P, Thongin S, Ketsawatsomkron P, Muta K. A model of hepatic steatosis with declined viability and function in a liver-organ-on-a-chip. Sci Rep 2023;13:17019.","DOI":"10.1038\/s41598-023-44198-0"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_010","doi-asserted-by":"crossref","unstructured":"Srivastava S, Chan C. Application of metabolic flux analysis to identify the mechanisms of free fatty acid toxicity to human hepatoma cell line. Biotechnol Bioeng 2008;99:399-410.","DOI":"10.1002\/bit.21568"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_011","doi-asserted-by":"crossref","unstructured":"Gori M, Simonelli MC, Giannitelli SM, Businaro L, Trombetta M, Rainer A. Investigating Nonalcoholic Fatty Liver Disease in a Liver-on-a-Chip Microfluidic Device. PLoS One 2016;11:e0159729.","DOI":"10.1371\/journal.pone.0159729"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_012","doi-asserted-by":"crossref","unstructured":"Lin Y, Ding D, Huang Q, Liu Q, Lu H, Lu Y, et al. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease. Biochim Biophys Acta Mol Cell Biol Lipids 2017;1862:869-882.","DOI":"10.1016\/j.bbalip.2017.05.001"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_013","doi-asserted-by":"crossref","unstructured":"Gerets HH, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, et al. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol 2012;28:69-87.","DOI":"10.1007\/s10565-011-9208-4"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_014","doi-asserted-by":"crossref","unstructured":"Pramfalk C, Larsson L, H\u00e4rdfeldt J, Eriksson M, Parini P. Culturing of HepG2 cells with human serum improve their functionality and suitability in studies of lipid metabolism. Biochim Biophys Acta 2016;1861:51-59.","DOI":"10.1016\/j.bbalip.2015.10.008"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_015","doi-asserted-by":"crossref","unstructured":"Lee PJ, Hung PJ, Lee LP. An artificial liver sinusoid with a microfluidic endothelial-like barrier for primary hepatocyte culture. Biotechnol Bio-eng 2007;97:1340-1346.","DOI":"10.1002\/bit.21360"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_016","doi-asserted-by":"crossref","unstructured":"Farhang Doost N, Srivastava SK. A Comprehensive Review of Organ-on-a-Chip Technology and Its Applications. Biosensors (Basel) 2024;14:225.","DOI":"10.3390\/bios14050225"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_017","doi-asserted-by":"crossref","unstructured":"Guo X, Xu H, Seo JE. Application of HepaRG cells for genotoxicity assessment: a review. J Environ Sci Health C Toxicol Carcinog 2024;42:214-237.","DOI":"10.1080\/26896583.2024.2331956"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_018","doi-asserted-by":"crossref","unstructured":"Guillouzo A, Corlu A, Aninat C, Glaise D, Morel F, Guguen-Guillouzo C. The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol Interact 2007;168:66-73.","DOI":"10.1016\/j.cbi.2006.12.003"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_019","doi-asserted-by":"crossref","unstructured":"Maseko TE, Elkalaf M, Peterov\u00e1 E, Lotkov\u00e1 H, Sta\u0148kov\u00e1 P, Melek J, et al. Comparison of HepaRG and HepG2 cell lines to model mitochondrial respiratory adaptations in nonalcoholic fatty liver disease. Int J Mol Med 2024;53:18.","DOI":"10.3892\/ijmm.2023.5342"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_020","doi-asserted-by":"crossref","unstructured":"van Wenum M, Adam AA, Hakvoort TB, Hendriks EJ, Shevchenko V, van Gulik TM, et al. Selecting cells for bioartificial liver devices and the importance of a 3D culture environment: A functional comparison between the HepaRG and C3A cell lines. Int J Biol Sci 2016;12:964-978.","DOI":"10.7150\/ijbs.15165"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_021","doi-asserted-by":"crossref","unstructured":"Farzaneh Z, Khojastehpour F, Keivan M, Farzaneh M. Co-culture of Liver Parenchymal Cells with Non-parenchymal Cells Under 2D and 3D Culture Systems; A Review. Curr Stem Cell Res Ther 2023;18:904-916.","DOI":"10.2174\/1574888X17666220614160957"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_022","doi-asserted-by":"crossref","unstructured":"Kumar M, Toprakhisar B, Van Haele M, Antoranz A, Boon R, Chesnais F, et al. A fully defined matrix to support a pluripotent stem cell derived multi-cell-liver steatohepatitis and fibrosis model. Biomaterials 2021;276:121006.","DOI":"10.1016\/j.biomaterials.2021.121006"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_023","doi-asserted-by":"crossref","unstructured":"Ros-Tarraga P, Villanueva-Badenas E, Sanchez-Gonzalez E, Gallego-Ferrer G, Donato MT, Tolosa L. Challenges of in vitro modelling of liver fibrosis. Front Cell Dev Biol 2025;13:1567916.","DOI":"10.3389\/fcell.2025.1567916"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_024","doi-asserted-by":"crossref","unstructured":"Kim B, Ronaldo R, Kweon BN, Yoon S, Park Y, Baek JH, et al. Mesenchymal stem cell-derived exosomes attenuate hepatic steatosis and insulin resistance in diet-induced obese mice by activating the FGF21-adiponectin axis. Int J Mol Sci 2024;25:10447.","DOI":"10.3390\/ijms251910447"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_025","doi-asserted-by":"crossref","unstructured":"Yang F, Wu Y, Chen Y, Xi J, Chu Y, Jin J, et al. Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate liver steatosis by promoting fatty acid oxidation and reducing fatty acid synthesis. JHEP Rep 2023;5:100746.","DOI":"10.1016\/j.jhepr.2023.100746"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_026","doi-asserted-by":"crossref","unstructured":"Dai Q, Zhu D, Du X, Tan H, Chen Q. Therapeutic potential of mesenchymal stem cell-derived extracellular vesicle in nonalcoholic fatty liver disease: a systematic review and meta-analysis of preclinical evidence. Lipids Health Dis 2025;24:217.","DOI":"10.1186\/s12944-025-02635-1"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_027","doi-asserted-by":"crossref","unstructured":"Wang Y, Pei YA, Sun Y, Zhou S, Zhang XB, Pei M. Stem cells immortalized by hTERT perform differently from those immortalized by SV40LT in proliferation, differentiation, and reconstruction of matrix microenvironment. Acta Biomater 2021;136:184-198.","DOI":"10.1016\/j.actbio.2021.09.021"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_028","doi-asserted-by":"crossref","unstructured":"Chen Q, Jin M, Wang S, Wang K, Chen L, Zhu X, et al. Establishing an hTERT-driven immortalized umbilical cord-derived mesenchymal stem cell line and its therapeutic application in mice with liver failure. J Tissue Eng 2023;14:20417314231200328.","DOI":"10.1177\/20417314231200328"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_029","doi-asserted-by":"crossref","unstructured":"Cerec V, Glaise D, Garnier D, Morosan S, Turlin B, Drenou B, et al. Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor. Hepatology 2007;45:957-967.","DOI":"10.1002\/hep.21536"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_030","doi-asserted-by":"crossref","unstructured":"Wang X, Wang L, Geng L, Tanaka N, Ye B. Resmetirom ameliorates NASH-Model Mice by Suppressing STAT3 and NF-\u03baB Signaling Pathways in an RGS5-Dependent Manner. Int J Mol Sci 2023;24:5843.","DOI":"10.3390\/ijms24065843"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_031","doi-asserted-by":"crossref","unstructured":"McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol 2015;172:3189-3193.","DOI":"10.1111\/bph.12955"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_032","doi-asserted-by":"crossref","unstructured":"Wang W, Zhao J, Gui W, Sun D, Dai H, Xiao L, et al. Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol 2018;175:469-484.","DOI":"10.1111\/bph.14095"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_033","doi-asserted-by":"crossref","unstructured":"Fang W, Du Z, Kong L, Fu B, Wang G, Zhang Y, et al. A rapid and sensitive single-cell proteomic method based on fast liquid-chromatography separation, retention time prediction and MS1-only acquisition. Anal Chim Acta 2023;1251:341038.","DOI":"10.1016\/j.aca.2023.341038"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_034","doi-asserted-by":"crossref","unstructured":"Wi\u015bniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods 2009;6:359-362.","DOI":"10.1038\/nmeth.1322"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_035","doi-asserted-by":"crossref","unstructured":"Takahashi Y, Dungubat E, Kusano H, Fukusato T. Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis. Comput Struct Biotechnol J 2023;21:2495-2501.","DOI":"10.1016\/j.csbj.2023.03.048"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_036","doi-asserted-by":"crossref","unstructured":"Ma CY, Zhai Y, Li CT, Liu J, Xu X, Chen H, et al. Translating mesenchymal stem cell and their exosome research into GMP compliant advanced therapy products: Promises, problems and prospects. Med Res Rev 2024;44:919-938.","DOI":"10.1002\/med.22002"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_037","doi-asserted-by":"crossref","unstructured":"Qiu L, Wang J, Chen M, Chen F, Tu W. Exosomal microRNA146a derived from mesenchymal stem cells increases the sensitivity of ovarian cancer cells to docetaxel and taxane via a LAMC2mediated PI3K\/Akt axis. Int J Mol Med 2020;46:609-620.","DOI":"10.3892\/ijmm.2020.4634"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_038","doi-asserted-by":"crossref","unstructured":"Jin X, Feng CY, Xiang Z, Chen YP, Li YM. CircRNA expression pattern and circRNA-miRNA-mRNA network in the pathogenesis of nonalcoholic steatohepatitis. Oncotarget 2016; 7: 66455-66467.","DOI":"10.18632\/oncotarget.12186"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_039","doi-asserted-by":"crossref","unstructured":"Xiong J, Chen G, He Y, Zhao C, Chen D, Liu Y, et al. Oxymatrine reduces hepatic lipid synthesis in rat model of nonalcoholic steatohepatitis by regulating Sirt1\/AMPK and LXR\/Plin2\/SREBP-1c pathways. Chem Biol Interact 2025;407:111370.","DOI":"10.1016\/j.cbi.2024.111370"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_040","doi-asserted-by":"crossref","unstructured":"Okumura T. Role of lipid droplet proteins in liver steatosis. J Physiol Biochem 2011;67:629-636.","DOI":"10.1007\/s13105-011-0110-6"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_041","doi-asserted-by":"crossref","unstructured":"Liu H, Yin G, Kohlhepp MS, Schumacher F, Hundertmark J, Hassan MIA, et al. Dissecting Acute Drug-Induced Hepatotoxicity and Therapeutic Responses of Steatotic Liver Disease Using Primary Mouse Liver and Blood Cells in a Liver-On-A-Chip Model. Adv Sci (Weinh) 2024;11:e2403516.","DOI":"10.1002\/advs.202403516"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_042","doi-asserted-by":"crossref","unstructured":"Pierfelice TV, D\u2019Amico E, Petrini M, Romano M, D\u2019Arcangelo C, Sbordone L, et al. A systematic review on organ-on-a-chip in PDMS or hydrogel in dentistry: An update of the literature. Gels 2024;10:102.","DOI":"10.3390\/gels10020102"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_043","doi-asserted-by":"crossref","unstructured":"Wang K, Zhang Y, Wang G, Hao H, Wang H. FXR agonists for MASH therapy: Lessons and perspectives from obeticholic acid. Med Res Rev 2024;44:568-586.","DOI":"10.1002\/med.21991"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_044","doi-asserted-by":"crossref","unstructured":"Zhang H, Dong X, Zhu L, Tang FS. Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease. World J Gastroenterol 2024;30:4393-4398.","DOI":"10.3748\/wjg.v30.i40.4393"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_045","doi-asserted-by":"crossref","unstructured":"Karim G, Bansal MB. Resmetirom: An Orally Administered, Small-molecule, Liver-directed, \u03b2-selective THR Agonist for the Treatment of Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis. touchREV Endocrinol 2023;19:60-70.","DOI":"10.17925\/EE.2023.19.1.60"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_046","doi-asserted-by":"crossref","unstructured":"Sun K, Zhu NL, Huang SL, Qu H, Gu YP, Qin L, et al. A new mechanism of thyroid hormone receptor \u03b2 agonists ameliorating nonalcoholic steatohepatitis by inhibiting intestinal lipid absorption via remodeling bile acid profiles. Acta Pharmacol Sin 2024;45:2134-2148.","DOI":"10.1038\/s41401-024-01303-x"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_047","doi-asserted-by":"crossref","unstructured":"Harrison SA, Taub R, Neff GW, Lucas KJ, Labriola D, Moussa SE, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2023;29:2919-2928.","DOI":"10.1038\/s41591-023-02603-1"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_048","doi-asserted-by":"crossref","unstructured":"Zhang C, Ji J, Du X, Zhang L, Song Y, Wang Y, et al. Atg5-deficient mesenchymal stem cells protect against non-alcoholic fatty liver by accelerating hepatocyte growth factor secretion. Cell Commun Signal 2024;22:579.","DOI":"10.1186\/s12964-024-01950-x"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_049","doi-asserted-by":"crossref","unstructured":"L. Li, Y. Liu, K. Wang, et al. Stem cell exosomes: new hope and future potential for relieving liver fibrosis. Clin Mol Hepatol. 2024.","DOI":"10.3350\/cmh.2024.0854"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_050","doi-asserted-by":"crossref","unstructured":"Jansen JC, Timal S, van Scherpenzeel M, Michelakakis H, Vicogne D, Ashikov A, et al. TMEM199 deficiency is a disorder of Golgi homeostasis characterized by elevated aminotransferases, alkaline phosphatase, and cholesterol and abnormal glycosylation. Am J Hum Genet 2016;98:322-330.","DOI":"10.1016\/j.ajhg.2015.12.011"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_051","doi-asserted-by":"crossref","unstructured":"Larsen LE, van den Boogert MAW, Rios-Ocampo WA, Jansen JC, Conlon D, Chong PLE, et al. Defective lipid droplet-lysosome interaction causes fatty liver disease as evidenced by human mutations in TMEM199 and CCDC115. Cell Mol Gastroenterol Hepatol 2022;13:583-597.","DOI":"10.1016\/j.jcmgh.2021.09.013"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_052","doi-asserted-by":"crossref","unstructured":"Orlicky DJ, Libby AE, Bales ES, McMahan RH, Monks J, La Rosa FG, et al. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions. J Physiol 2019;597:1565-1584.","DOI":"10.1113\/JP277140"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_053","doi-asserted-by":"crossref","unstructured":"Libby AE, Bales E, Orlicky DJ, McManaman JL. Perilipin-2 deletion impairs hepatic lipid accumulation by interfering with sterol regulatory element-binding protein (SREBP) activation and altering the hepatic lipidome. J Biol Chem 2016;291:24231-24246.","DOI":"10.1074\/jbc.M116.759795"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_054","doi-asserted-by":"crossref","unstructured":"McManaman JL, Bales ES, Orlicky DJ, Jackman M, MacLean PS, Cain S, et al. Perilipin-2-null mice are protected against diet-induced obesity, adipose inflammation, and fatty liver disease. J Lipid Res 2013;54:1346-1359.","DOI":"10.1194\/jlr.M035063"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_055","doi-asserted-by":"crossref","unstructured":"Sookoian S, Casta\u00f1o G, Gianotti TF, Gemma C, Pirola CJ. Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J Nutr Biochem 2009;20:765-770.","DOI":"10.1016\/j.jnutbio.2008.07.005"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_056","doi-asserted-by":"crossref","unstructured":"Hardwick RN, Fisher CD, Street SM, Canet MJ, Cherrington NJ. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab Dispos 2012;40:450-460.","DOI":"10.1124\/dmd.111.041095"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_057","doi-asserted-by":"crossref","unstructured":"Xie F, Qu J, Lin D, Feng K, Tan M, Liao H, et al. Reduced Proteolipid Protein 2 promotes endoplasmic reticulum stress-related apoptosis and increases drug sensitivity in acute myeloid leukemia. Mol Biol Rep 2023;51:10.","DOI":"10.1007\/s11033-023-08994-1"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_058","doi-asserted-by":"crossref","unstructured":"Lorenzon-Ojea AR, Yung HW, Burton GJ, Bevilacqua E. The potential contribution of stromal cell-derived factor 2 (SDF2) in endoplasmic reticulum stress response in severe preeclampsia and labor-onset. Biochim Biophys Acta Mol Basis Dis 2020;1866:165386.","DOI":"10.1016\/j.bbadis.2019.01.012"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_059","doi-asserted-by":"crossref","unstructured":"Lorenzon AR, Moreli JB, de Macedo Melo R, Namba FY, Staff AC, Yung HW, et al. Stromal cell-derived factor (SDF) 2 and the endoplasmic reticulum stress response of trophoblast cells in gestational diabetes mellitus and in vitro hyperglycaemic condition. Curr Vasc Pharmacol 2021;19:201-209.","DOI":"10.2174\/1570161118666200606222123"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_060","doi-asserted-by":"crossref","unstructured":"Vandervore LV, Schot R, Milanese C, Smits DJ, Kasteleijn E, Fry AE, et al. TMX2 is a crucial regulator of cellular redox state, and its dysfunction causes severe brain developmental abnormalities. Am J Hum Genet 2019;105:1126-1147.","DOI":"10.1016\/j.ajhg.2019.10.009"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_061","doi-asserted-by":"crossref","unstructured":"Zhang L, Wang T, Valle D. Reduced PLP2 expression increases ER-stress-induced neuronal apoptosis and risk for adverse neurological outcomes after hypoxia ischemia injury. Hum Mol Genet 2015;24:7221-7226.","DOI":"10.1093\/hmg\/ddv422"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_062","doi-asserted-by":"crossref","unstructured":"Wang W, Zhong X, Guo J. Role of 2series prostaglandins in the pathogenesis of type 2 diabetes mellitus and nonalcoholic fatty liver disease (Review). Int J Mol Med 2021;47:114.","DOI":"10.3892\/ijmm.2021.4947"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_063","doi-asserted-by":"crossref","unstructured":"Fu Y, Zhang S, Zeng X, Qin H. Association Between Alpha-1-Acid Glycoprotein and Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Adult Women. Metabolites 2025;15:280.","DOI":"10.3390\/metabo15040280"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_064","doi-asserted-by":"crossref","unstructured":"Gunning PW, Hardeman EC, Lappalainen P, Mulvihill DP. Tropomyosin - master regulator of actin filament function in the cytoskeleton. J Cell Sci 2015;128:2965-2974.","DOI":"10.1242\/jcs.172502"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_065","doi-asserted-by":"crossref","unstructured":"Wu Y, Zuo J, Ji G, Saiyin H, Liu X, Yin F, et al. Proapoptotic function of integrin beta(3) in human hepatocellular carcinoma cells. Clin Cancer Res 2009;15:60-69.","DOI":"10.1158\/1078-0432.CCR-08-1028"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_066","doi-asserted-by":"crossref","unstructured":"Liao KA, Rangarajan KV, Bai X, Taylor JM, Mack CP. The actin depolymerizing factor destrin serves as a negative feedback inhibitor of smooth muscle cell differentiation. Am J Physiol Heart Circ Physiol 2021;321:H893-H904.","DOI":"10.1152\/ajpheart.00142.2021"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_067","doi-asserted-by":"crossref","unstructured":"Zhang Z, Bie X, Chen Z, Liu J, Xie Z, Li X, et al. A novel variant of DNM1L expanding the clinical phenotypic spectrum: a case report and literature review. BMC Pediatr 2024;24:104.","DOI":"10.1186\/s12887-023-04442-y"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_068","doi-asserted-by":"crossref","unstructured":"Nolden KA, Egner JM, Collier JJ, Russell OM, Alston CL, Harwig MC, et al. Novel DNM1L variants impair mitochondrial dynamics through divergent mechanisms. Life Sci Alliance 2022;5:e202101284.","DOI":"10.26508\/lsa.202101284"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_069","doi-asserted-by":"crossref","unstructured":"He J, Ford HC, Carroll J, Douglas C, Gonzales E, Ding S, et al. Assembly of the membrane domain of ATP synthase in human mitochondria. Proc Natl Acad Sci USA 2018;115:2988-2993.","DOI":"10.1073\/pnas.1722086115"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_070","doi-asserted-by":"crossref","unstructured":"Gao R, Li Y, Xu Z, Zhang F, Xu J, Hu Y, et al. Mitochondrial pyruvate carrier 1 regulates fatty acid synthase lactylation and mediates treatment of nonalcoholic fatty liver disease. Hepatology 2023;78:1800-1815.","DOI":"10.1097\/HEP.0000000000000279"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_071","doi-asserted-by":"crossref","unstructured":"Cheong A, Lingutla R, Mager J. Expression analysis of mammalian mitochondrial ribosomal protein genes. Gene Expr Patterns 2020;38:119147.","DOI":"10.1016\/j.gep.2020.119147"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_072","doi-asserted-by":"crossref","unstructured":"Tajima Y, Kawashima I, Tsukimura T, Sugawara K, Kuroda M, Suzuki T, et al. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am J Hum Genet 2009;85:569-580.","DOI":"10.1016\/j.ajhg.2009.09.016"},{"key":"2026021906293001311_j_jtim-2026-0007_ref_073","doi-asserted-by":"crossref","unstructured":"Chen L, Lu Y, Zhao M, Xu J, Wang Y, Xu Q, et al. A non-canonical role of endothelin converting enzyme 1 (ECE1) in promoting lung cancer development via directly targeting protein kinase B (AKT). J Gene Med 2024;26:e3612.","DOI":"10.1002\/jgm.3612"}],"container-title":["Journal of Translational Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0007\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0007\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:30:25Z","timestamp":1771482625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jtim-2026-0007\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,29]]},"published-print":{"date-parts":[[2026,2,18]]}},"alternative-id":["10.1515\/jtim-2026-0007"],"URL":"https:\/\/doi.org\/10.1515\/jtim-2026-0007","relation":{},"ISSN":["2224-4018"],"issn-type":[{"value":"2224-4018","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}